Product name:CIPROFLOXACIN TABLETS USP
Company name:
DIN:02248578
Status:Marketed
Status date:2023-05-11
| Active ingredient(s) | Strength |
|---|---|
| CIPROFLOXACIN (CIPROFLOXACIN HCL) | 250 MG |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
We will be providing an updated, customized prescription drug information sheet, with information on the drug ciprofloxacin, based on the drug information available on the patient’s pharmacy. The new drug information sheet will include the following: • Drug interaction information • Prescription drug information • Dosage form and administration • Dosage and administration method • Patient’s age, race, and location • Drug interactions • Dosage and administration • Dosage adjustments • Prescription drug information • Cost of ciprofloxacin • Patient’s medical history • Dosage adjustments to ensure drug safety and effectiveness
In this news release, please note that the drug ciprofloxacin is not a prescription drug. It is a new class of medicine called a fluoroquinolone class of drugs.
The prescribing information for ciprofloxacin is available on the patient’s pharmacy, and it will be reviewed by the medical practitioner. We will also add information on the cost of ciprofloxacin to the patient’s pharmacy.
Our prescriber will review the patient’s medical records, including the prescribing information, for any new or previously unknown drug interactions and the dosage and administration of the drug.
This information is updated regularly and will be reviewed periodically by the medical practitioner. Please refer to the Patient Information leaflet for more information.
Please Note:The information provided here is intended to be an educational tool to help patients learn about the new drugs and how to use them safely. It is not intended to replace the advice of a physician, pharmacist, or other health care professional, and should not be considered a replacement for professional consultation with your individual physician, pharmacist, or health care provider. Always consult with your health care provider before starting or stopping any medication.
This information is provided for informational purposes only. It is not a substitute for professional medical advice. You should not rely upon the content provided in this article for specific medical conditions, health advice, or advice regarding your individual health. If you have any questions or concerns, please talk to your doctor or pharmacist.Additional information:
We recommend that you consult with your doctor or pharmacist before using any new prescription drug information, drug information, or product information in connection with any health or medical condition. They may be able to suggest additional resources or information.
This data is used by third parties for educational purposes only. The information provided here is not meant to endorse or recommend any product or brand. The information in this leaflet is not meant to substitute professional medical advice, diagnosis, or treatment. It is not intended to endorse any medication or drug combination, or recommend that any individual find a proper dosage of any medication. It is not a substitute for independent research or advice from a health care professional. You should consult with your doctor before beginning any medical or health product. Your doctor may also be able to suggest a different treatment or drug for a particular medical condition. This information is not intended to be a substitute for professional medical advice. It is always best to consult with a healthcare professional if you have a medical condition or financial risk. Third-party payors may be able to pay for your own research and/or subscription services via pay-for-search services or paid-for-by services.References:
Rosenbaum, A. (2000). A guide to prescribing oral ciprofloxacin: A national survey of health care professionals. Medscape. [cited]. Available at:
(2002). Oral fluoroquinolone antibiotics and their use in the treatment of severe bacterial infections: A systematic review. Infectious Diseases Society of America. Retrieved July 29, 2005, from
Tajani, R., Kaul, B. B., Kamble, C. J., & Kim, H. K. (2001). Pharmacogenetics and antibiotic susceptibility of the susceptible isolates ofStreptococcus pneumoniae. Antimicrob. Agents Chemother. (2003). Accessed November 5, 2005,
Chen, Y. Q., & Lin, W. L. Effect of ciprofloxacin on susceptibility ofto the quinolones. J. Clin. Microbiol. (2004).
Liu, B. W., Sohn, H.
This study describes the price of the combination of ciprofloxacin and doxycycline in patients with acute bacterial sinusitis. We assessed the impact of the combination on the incidence of mortality in this cohort. Our analysis was performed using data from the Medicare Part D study. We used the same methodology to describe the results of the study.
The prevalence of bacterial infections is rising worldwide. The Centers for Disease Control and Prevention (CDC) estimates that in 2015, the total number of bacterial infections caused by any cause was 3.4 million, with an incidence of 4.3 million in the United States alone. Bacterial infections are one of the most common bacterial diseases worldwide [,]. In the United States, approximately 30% of all infections are considered a “chronic” disease. The rising incidence of bacterial infections is expected to lead to the need for treatment to combat the disease. The prevalence of bacterial infections is increasing, and the Centers for Disease Control and Prevention (CDC) estimates that the incidence of bacterial infections in the United States is approximately 13% per year [,].
Bacterial infections are treatable by using drugs to inhibit bacterial growth. Antibiotic drugs are commonly used to treat bacterial infections such as UTIs, bronchitis, and sinusitis. Antibiotics are used to treat infections that have already been cleared, such as sexually transmitted infections, and are being treated in an emergency care setting. The CDC estimates that the rate of bacterial infections will increase over the next several decades due to a combination of the increasing prevalence of bacterial infections and the need for antimicrobial agents [,]. However, the use of antibiotics for the treatment of bacterial infections in the United States has been limited. This study presents the price of ciprofloxacin and doxycycline in the United States, as well as their cost and the impact of the combination on the incidence of mortality in this cohort.
We reviewed the Medicare Part D study, the National Health Insurance Survey (NHIS), from 2015 to 2019. The NHIS covers all Medicare Part D costs. The Medicare Part D study includes a total of 3,842,841 beneficiaries with a diagnosis of acute bacterial sinusitis in the United States. The Medicare Part D study covers all Medicare Part D costs, including co-payments for the drug, hospital admissions, and treatment, and the co-payment for the drug and the hospital admission. The Medicare Part D study includes an annual deductible, which is the amount of a patient’s health plan covered by the plan. Medicare Part D also covers the cost of both the drug and the hospital admission. The Medicare Part D study covers co-payments for the drug and the hospital admission, as well as the costs of both the drug and the hospital admission. The Medicare Part D study is a retrospective study of the cost of the drug and hospital admission in the United States. The cost of the drug and hospital admission is based on the plan’s prescription drug coverage, and the hospital admissions are based on the plan’s prescription drug coverage. The cost of the drug and the hospital admission is based on the plan’s co-payment and the co-payment for the drug and the hospital admission. For the diagnosis of acute bacterial sinusitis, the Medicare Part D study covers both the drug and the hospital admission, as well as the cost of both the drug and the hospital admission.
The Medicare Part D study includes a total of 2,845,092 beneficiaries with a diagnosis of acute bacterial sinusitis in the United States. The Medicare Part D study includes a total of 2,845,841 beneficiaries with a diagnosis of acute bacterial sinusitis in the United States. The Medicare Part D study covers co-payments for the drug and hospital admissions, as well as the costs of both the drug and the hospital admission.
The costs of the drug and hospital admission are based on the plan’s prescription drug coverage. Medicare Part D covers the cost of both the drug and the hospital admission, as well as the costs of both the drug and the hospital admission.
The Medicare Part D study covers the cost of the drug and the hospital admission, as well as the cost of both the drug and the hospital admission.
Cipro HC is used to treat bacterial infections of the urinary tract and lower the risk of recurrent UTIs (urinary tract infections) caused by susceptible bacteria. It is also used to treat infections of the skin and soft tissues, as well as certain types of lower respiratory tract infections.
Cipro HC is not effective for most bacterial infections, but it can help reduce the risk of recurrent UTIs when used with antibiotics. It is also used in the treatment of acne.
In clinical trials, it was found to be effective in eliminating bacteria and reducing the risk of urinary tract infections in patients who have a history of recurrent UTIs.
Cipro HC is available in the following strengths:
If you have used Cipro HC for more than 1 week, it is important to read the patient information leaflet.
You should use Cipro HC as directed by your doctor, but you should not use other medications, such as antibiotics, except with the guidance of your doctor.
You should not use Cipro HC if you are allergic to ciprofloxacin, ciprofloxacin, levofloxacin, or any other antibiotics, or if you have a history of liver problems.
Do not drink alcohol with Cipro HC. It can increase the chance of side effects.
Do not use Cipro HC without telling your doctor if you are pregnant, breastfeeding, or taking any other medications.
Before taking Cipro HC, be sure to tell your doctor if you have any of the following:
It is important that you do not drink alcohol while you are using Cipro HC.
Cipro HC may cause a rash or a skin condition called Stevens-Johnson syndrome. These conditions are rare, but if you have a history of these conditions, you should tell your doctor.
Cipro HC is not recommended for women, especially those who have an increased risk of breast cancer, due to the risk of liver disease and bone fractures. It is not known if Cipro HC is excreted in breast milk.
Do not use Cipro HC if you are breastfeeding. Your doctor will decide how much you should take and if you should continue to breastfeed. Cipro HC is not recommended for children under 12 years old due to the risk of bone fractures in these age groups.
Like all medicines, Cipro HC may cause side effects. Tell your doctor if any of the following side effects are severe or do not go away:
If you experience any of the following side effects, stop taking Cipro HC and contact your doctor immediately:
You should not use Cipro HC if you have had a severe allergic reaction to ciprofloxacin, erythromycin, or any other medicines.
Stade de France Pharmacy